Cardiovascular and Metabolic Diseases

Cardiovascular and Metabolic (CVM) research focuses on discovering and developing innovative mechanism-based compounds directed against novel disease targets, to treat a broad range of cardiovascular and metabolic diseases. For many common heart and metabolic diseases, a number of treatment options exist, but the conditions are often poorly controlled. Novartis has a longstanding commitment to researching cardiovascular and metabolic disease and has developed major medicines in the field.

While the CVM Disease Area continues to seek to optimize treatment of risk factors (blood pressure, hyperglycemia, dyslipidemia), their strategic efforts aim to directly address disease effects at target organs (e.g., diastolic heart failure, nephropathy, beta–cell protection, vascular compliance) and to fundamentally reset metabolic dysregulation.

CVM concentrates on type 2 diabetes, arthrosclerosis, heart failure and hypertension.

 

 

Selected publications

• Zeggini, E.; Scott, L. J.; Saxena, R. & Voight, B. F., for the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. (May 2008); 40(5): 638-45. Epub Mar 30, 2008.
• Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes for BioMedical Research. Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels. Science  (June 1, 2007); 316: 1331-1336; published online April, 26 2007.